A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas

Haematologica. 2021 Apr 1. doi: 10.3324/haematol.2021.278301. Online ahead of print.ABSTRACTNot available.PMID:33792222 | DOI:10.3324/haematol.2021.278301

Source: Haematologica - April 1, 2021 Category: Hematology Authors: Miso Kim Jeong-Ok Lee Jiwon Koh Tae Min Kim Ji Yun Lee Yoon Kyung Jeon Bhumsuk Keam Dong-Wan Kim Jong Seok Lee Dae Seog Heo Source Type: research